OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2021.13111 OL-22-06-13111 Review DCLK1 and its interaction partners: An effective therapeutic target for colorectal cancer VijaiMuthu BabaMursaleen RamalingamSatish ThiyagarajAnand Department of Genetic Engineering, SRM Institute of Science and Technology, Sri Ramaswamy Memorial (SRM) Nagar, Kattankulathur, Tamil Nadu 603203, India Correspondence to: Dr Anand Thiyagaraj, Department of Genetic Engineering, SRM Institute of Science and Technology, Sri Ramaswamy Memorial (SRM) Nagar, B508 Bioengineering Block, Kattankulathur, Tamil Nadu 603203, India, E-mail: anandt@srmist.edu.in 12 2021 26 10 2021 22 6 850 03122020 02062021 Copyright: © Vijai et al. 2021 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Doublecortin-like kinase protein 1 (DCLK1) is a microtubule-associated protein with a C-terminal serine/threonine kinase domain. Its expression was first reported in radial glial cells, where it serves an essential role in early neurogenesis, and since then, other functions of the DCLK1 protein have also been identified. Initially considered to be a marker of quiescent gastrointestinal and pancreatic stem cells, DCLK1 has recently been identified in the gastrointestinal tract as a marker of tuft cells. It has also been implicated in different types of cancer, where it regulates several vital pathways, such as Kras signaling. However, its underlying molecular mechanisms remain unclear. The present review discusses the different roles of DCLK1 and its interactions with other proteins that are homologically similar to DCLK1 to develop a novel therapeutic strategy to target cancer cells more accurately.

 doublecortin-like kinase protein 1 colorectal cancer tuft cells stem cell niche cancer-initiating cells Introduction

Doublecortin-like kinase protein 1 (DCLK1), also known as DCAMLK1 and CLICK1, was first identified in the developing rodent brain as a brain-specific protein (1,2). The DCLK1 gene is present on the 13q13.3 loci of the human chromosome 13, and codes for a member from the protein kinase superfamily and the doublecortin family (2). The DCLK1 protein contains two N-terminal doublecortin domains, which bind to microtubules and regulate their polymerization, while its C-terminal serine/threonine-protein kinase domain, with substantial homology to Ca2+/calmodulin-dependent protein kinase (3–6), is in between the doublecortin and the protein kinase domains, mediating multiple protein-protein interactions (7). Previous studies have reported that this protein is highly expressed in the radial glial cells and neuronal precursors, suggesting a potential role in early neurogenesis (3,4,7).

DCLK1 is expressed in tuft cells of the gastrointestinal tract, and is also expressed at low levels in normal gastrointestinal cells and upregulated in several gastrointestinal malignancies (8). It is also considered a marker in cancer stem cells and cancer-initiating cells (8–11). The DCLK1 gene is speculated to serve a role in the epithelial-to-mesenchymal transition (EMT) of tumor cells by regulating the NOTCH, WNT and NFKB signaling pathways (12,13). Fig. 1 illustrates the important findings of DCLK1 throughout the years. Proteins that share similar functional homology and co-expression patterns have been demonstrated to interact with each other (14). The present review discusses proteins that exhibit homology, co-expression or interaction with DCLK1. Previous studies have reported the role of DCLK1 in cancer cell self-renewal (14,15). Thus, it is important to identify a novel inhibitor for DCLK1.

 Functions of DCLK1 and its role in cancer <sec> <title>Normal function of DCLK1

DCLK1 is highly expressed in tuft cells of the gastrointestinal tract. These tuft cells are similar to taste cells and serve a chemosensory role in the small intestine and colon (16). However, their primary function is to initiate a T helper cell immune response against parasites (17). Tuft cells exhibit self-renewal proliferative abilities due to the expression of DCLK1 (18). The microtubule-associated protein coded by DCLK1 has three major splice variants (DCLK, DCLK DCX-like and CPG16), with altered kinase activities. In addition, DCLK1 exhibits differential splicing in embryonic tissues compared with adult tissues (5). The embryonic forms of DCLK1 and DCLK-like proteins exhibit considerably higher expression in post-mitotic neurons and neuronal progenitor cells (radial glial cells) compared with other neuronal cells (5). The post-mitotic neurons also express DCX (3,5). Furthermore, DCLK1 is highly expressed in developing mammalian brains, particualry in the neocortex and cerebellum regions, where active neurogenesis occurs. However, this expression is diminished in adults (19). DCLK1 stimulates the polymerization of tubulins while interacting with microtubulins through the tandem DCX domains, and is highly expressed in the brain (5).

Given that the temporal and spatial expression pattern of doublecortin is very similar to that of DCLK1, DCLK1 is proposed to have functions similar to that of doublecortin (20,21). Thus, it may serve a role in neuronal migration, axon transport, synapse maturation and brain development (21–24). Furthermore, DCLK1 has two isoforms of varying lengths because of the epithelial changes that occur with different functions, where the shorter isoform DCLK1-S induces tumorigenesis in colorectal cancer (CRC) (7,25,26). DCLK1 labels a subset of dendritic microtubules and is required for trafficking KIF1-dependent dense-core vesicles into dendrites and dendritic development (23). Although these tuft cells have significant self-renewal properties, they are not stem cells. Lineage tracing studies have demonstrated that while these cells can be a part of the reserve progenitor cells that originate from rapidly cycling or quiescent stem cells, they do not exhibit lineage tracing similar to that of the stem cells while resting or under duress (27–30). Thus, they cannot be considered quiescent or active intestinal stem cells (30). DCLK1 helps in maintaining intestinal homeostasis, along with assisting tissue regeneration (8,31–32). Thus, knocking down DCLK1 in mouse models of DDS-induced colitis followed by completely irradiating it results in the loss of DCLK1, exacerbating tissue injury and halting the tissue regeneration (33,34). However, whether this is due to a deficiency in the critical tuft cell-derived niche factors or a contribution to the regenerative program by DCLK1-expressing epithelial cells remains to be investigated (35,36).

 DCLK1 expression in cancer

DCLK1 performs a variety of functions associated with tumorigenesis (37). The malignancy of every cancer is dependent on the metastasizing ability of a tumor; for example, the ability to move to a different organ. Angiogenesis and EMT are essential for the metastasis of cancer cells. DCLK1 regulates metastasis by controlling signaling pathways, such as the NOTCH, WNT, RTK, TGF-β and Hedgehog pathways (37). DCLK1 is also associated with the enhancement of angiogenesis in pancreatic tumors (38). Upregulation of the DCLK1 gene downregulates microRNA (miRNA/miR)-200a expression, which in turn upregulates the expression of EMT-related transcription factors, such as ZEB1, ZEB2, SNAIL and SLUG (25,39), resulting in increased angiogenesis and metastasis. Similarly, upregulation of DCLK1 also downregulates miR-143/145 expression in CRC and pancreatic cancer, which increases the expression of maintenance factors, such as NANOG, OCT4, KLF4, SOX2, RREB1 and KRAS, eventually increasing the pluripotency tumorigenicity of these types of cancer (40,41). DCLK1 serves a role in various cancer functions, such as drug resistance, metastasis, secondary tumor formation and cancer recurrence (12,42–46). In addition, it helps regulate cell proliferation and invasion in Hodgkin's lymphoma (47). Overexpression of DCLK1 in primary human hepatocytes has been demonstrated to form spheroids in suspension cultures. Furthermore, these cells express high levels of β-catenin, α-fetoprotein and SOX9, suggesting that DCLK1 can induce clonogenicity in hepatoma cells (48). Table I illustrates the role of DCLK1 in three of the most prevalent types of cancer. It also lists information on different proteins and pathways regulated by DCLK1.

 DCLK1 as a cancer stem cell marker

Analyzing pre-invasive pancreatic cancer cells in mouse models has demonstrated that a subpopulation of these cancer cells are morphologically similar to the gastrointestinal tuft cells, with similar stem cell-like properties (49). It has also been reported that DCLK1 is highly expressed in these cells, serving as a potential biomarker for cancer stem cells (50). Following this discovery, it has been demonstrated that DCLK1 has similar biomarker properties in CRC and osteosarcoma (50). Immunoassay methods were performed to identify circulating cellular protein DCLK1 in CRC stem cells, proving it to be the most promising cancer stem cell marker (51–54). Thus, DCLK1 is not just a target for diagnostic purposes but is also useful in therapeutic settings (12,42,55–59).

 DCLK1 as a therapeutic target for cancer

Targeting DCLK1 with antibodies has helped accurately screen for CRC (60). Inhibition of DCLK1 using miR-137 and other alternate splicing methods is effective in decreasing tumorigenesis in CRC and kidney cancer (10). miR-195 targets DCLK1 and successfully reduces the pluripotency and EMT in pancreatic cancer cells (61). It is also targeted in non-small cell lung carcinoma to increase chemosensitivity of the cancer cells (62). In CRC, the sensitivity of cancer cells against chemotherapy and radiation therapy is enhanced by targeting DCLK-KRAS, using miR-15b (63). DCLS-KRAS is associated with increased tumor cell invasion in 95% of pancreatic ductal adenocarcinomas (PDAC), and is also considered an undruggable target (63). DCLK1 is associated with increased KRAS expression via the PI3K/AKT/mTOR-pathway (40). Thus, DCLK1 can potentially be targeted to decrease KRAS expression and control tumor cell invasion in PDAC.

The B cell-specific moloney murine leukemia virus insertion site 1 (Bmi-1) is a crucial regulator for the self-renewal, malignant transformation and EMT of cancer stem cells, and is upregulated in pancreatic cancer (64). DCLK1 knockdown suppresses cell proliferation, both in vitro and in vivo, and inhibits the migration and invasion capacities of pancreatic cancer cells by decreasing Bmi-1 expression; thus, suggesting a potential novel strategy to treat pancreatic cancer (64). It has been reported that DCLK1 can be selectively silenced using let-7a miRNA, which arrests tumor growth in human CRC cells (65). Recently, it was demonstrated that the co-localization of DCLK1 with autophagy-related protein p62 happens due to accumulation of DCLK1 in colon cancer cells (65). In addition, crocetinic acid targets DCLK1 in cancer cells by inhibiting the hedgehog signaling pathway in pancreatic cancer cells (65).

 DCLK1 and its interacting partners <sec> <title>DCLK1 and DCX

DCX or doublecortin is present on the X chromosome at Xq23 and codes for the doublecortin family of proteins (66,67). DCX is a cytoplasmic microtubule-associated protein that helps stabilize microtubules (68–70). DCX and DCLK1 have protein profiles with very high homology and similar functions (71), suggesting a functional redundancy or functional equivalence. Their functional association was assessed by knocking down the DCLK gene via the RNAi strategy in rats. The results demonstrated that a dose-dependent interaction exists between DCX and DCLK1 in commissural fiber tract formation (72), which is also associated with humans, although not proven by experimental procedures (73,74). In humans, DCX and DCLK1 are hypothesized to compete with each other to bind to the target proteins. This competitive binding may be a way for either protein to participate in a signaling pathway crucial for neuronal interaction before and during migration, which may be part of a calcium ion-dependent signal transduction pathway (75). Fig. 2 presents the co-expression of DCLK1 and DCX, and demonstrates the interaction between them.

 DCLK1 and ANK2

The ANK2 gene codes for a family of proteins that play key roles in cellular functions, such as cell motility, activation, proliferation, cell-cell contact signaling and the maintenance of specialized membrane domains (76). In humans, the ANK2 and DCLK1 genes are implicated in co-expression networks, with an RNA co-expression score of 0.305 (Fig. 2) (71). ANK2, similarly to DCLK1, serves a role in the progression of gastric cancer. While DCLK1 plays a role in promoting the EMT process of gastric cancer and helps in lymphovascular invasion (77,78), ANK2 serves a role in promoting the proliferation of the cancer cells. Targeting and silencing ANK2 using miR-647 inhibits the proliferation of gastric cancer cells (79,80). Notably, while trying to identify the genes regulating normal hearing, an audiometric pattern has been observed in the expression of the genes. Differences between different mice genotypes have also been observed, supporting ANK2′s role in hearing function (81–83).

 DCLK1 and MSI1

The MSI1 gene, also known as Musashi RNA binding protein 1, encodes a protein containing two conserved tandem RNA recognition motifs (83). Similar proteins in other species function as RNA-binding proteins, playing central roles in post-transcriptional gene regulation (84). The MSI1 protein is associated with various factors, including the grade of the malignancy, proliferative activity in glioma melanomas, esophageal cancer and colon cancer (85–87). The MSI1 gene was initially identified as a neuronal stem cell marker, which can affect cell cycle regulation, proliferation and apoptosis by suppressing the expression of certain mRNAs and other genes (88,89). The MSI1 gene, similar to the DCLK1 gene, is also an intestinal stem cell marker, which is expressed alongside DLCK1 in gastric cancer cells (90). Targeting and silencing of the MSI1 gene activates certain tumor-suppressing mRNAs, inhibiting the growth of cancers (88,91–93). The Musashi RNA binding protein activates the WNT and NOTCH signaling pathways to regulate proliferation (91). In humans, the MSI1 and DCLK1 genes are a part of multiple co-expression networks (71), and it has been reported that DCLK1 is often expressed in cells that also express the MSI1 gene, namely the long-lived tuft cells (94). This suggests that MSI1 may interact with DCLK1 to help tumor progression.

 TNIK and CALM1 proteins

According to GeneMANIA (https://genemania.org), DCLK1 physically interacts with TRAF2 and NCK interacting Kinase (TNIK) and calmodulin (CALM1) proteins (95). The TNIK protein is an activator of the WNT signaling pathway, which is regulated in several types of cancer, including CRC (96). Thus, DCLK1 can directly or indirectly interact with TNIK to regulate the WNT signaling pathway. The CALM1 protein mediates the control of various enzymes, ion channels, aquaporins and other proteins via calcium-binding (97). The C-terminal of the DCLK1 protein has a serine/threonine-protein kinase domain, which exhibits substantial homology to Ca2+/calmodulin-dependent protein kinase, making it possible for the CALM1 protein to regulate DCLK1 through its domain (Fig. 2).

 Genomic evidence

In 2015, scientists performed a series of genomic experiments to identify the protein interactions, where high-throughput affinity purification mass spectroscopy was performed to identify the interacting partners of 2,594 proteins in HEK293T cells (75). The resulting network (BioPlex) revealed 23,744 interactions among 7,668 proteins, with 86% interactions previously undocumented (75). In 2017, the same scientists released Bioplex 2.0, which contained interacting partners of 25% of protein-coding genes, with >29,000 previously unknown co-associations (76). According to the Bioplex 2.0 network, the highest-scoring interacting proteins with DCLK1 were cell division cycle associated 8 (CDCA8), deoxyguanosine kinase (DGUOK), filamin binding LIM protein 1 (FBLIM1), HCLS1-associated protein X1 (HAX1) and nuclear FMR1 interacting protein (NUFIP1). All these five proteins were found to be molecular targets of DCLK1. CDCA8 plays roles in mitosis and cell division, and also helps in chromatin-induced microtubule stabilization (98). Being a microtubule-associated protein, DCLK1 may be associated with CDCA8. Overexpression of CDCA8 promotes proliferation of bladder cancer cells (98). DGUOK has a similar kinase function to DCLK1 and can regulate cancer cell stemness (99). FBLIM1 helps in cell adhesion and motility (100), and when overexpressed in glioma, it increases cancer cell migration, which can be induced by DCLK1 as it plays a role in angiogenesis and metastasis (100). HAX1 is a potential oncogene for hypopharyngeal carcinoma, which increases cancer cell proliferation and migration (101). The NUFIP1 protein interacts with the tumor suppressor protein, BRCA (102). Notably, proteins with high scores have an implicated role in different types of cancer.

 DCLK1 as a potential small-molecule target in CRC

The aforementioned profile insights of the DCLK1 gene prove that they are key components of CRC pathogenesis (13). Targeting the DCLK1 kinase domain to inhibit its function may be an effective strategy for treating CRC (52). The interaction profile of DCLK1, along with its co-expressing genes, seem to share a strong homology (52,103); thus, there is a requirement for a specific small molecule to inhibit DCLK1. It has been demonstrated that the inhibitor of Leucine-rich repeat kinase 2 (LRRk) protein, LRRk2-IN-1, a key regulator in Alzheimer's disease, inhibits DCLK1 in vitro (103). Recently, an analog of LRRk2-IN-1 was designed and successfully tested as a DCLK1 inhibitor (Fig. 3) (103). Although these small molecules are effective, there is ambiguity regarding their non-specificity to DCLK1, since DCLK1 also has strong homology to other interaction partners (103,104). Thus, 3D pharmacophore-based strategy for high throughput virtual screening (HTVS) can be applied against a natural compound databases (105). These databases have millions of compounds that are commercially available. Thus, HTVS combined with molecular docking and molecular dynamics studies may provide insights into secondary structure changes induced by small-molecule binding. Such computational methods combined with in vitro validation can help identify effective inhibitors for DCLK1 (105). Furthermore, building a pharmacophore model from molecular dynamics simulations of LRRk2-IN-1, which is a recent approach in identifying potential small moleculae inhibitors, can be an effective strategy in designing a novel small molecule inhibitor for DCLK1 (106). A computational quantum mechanical modeling method, such as density functional theory, can be used to study the electronegativity of these small molecules interacting with DCLK1 (107–109).

 Conclusion

DCLK1 was initially identified for its function in neuronal development, but has recently been implicated as an epigenetic marker in tuft cells of the intestine, and also in tumorigenesis. DCLK1 interacts with several proteins and regulates various pathways to perform functions, ranging from cancer initiation to metastasis. Understanding the pathways and their interactions with DCLK1 is important to develop effective treatment strategies for different types of cancer. Currently, targeting and silencing DCLK1 using small molecule kinase inhibitors is a good therapeutic strategy for treating colorectal cancer. However, this strategy is non-specific and thus is inefficient. In addition, the underlying molecular mechanisms of DCLK1 remain unclear. Proteins with a similar homology and co-expression pattern to DCLK1 can be used to determine the exact molecular mechanism of the protein. With the development of techniques, such as next-generation 3D pharmacophore modeling, the profiles of DCLK1 and its interaction partners can be extensively investigated (110–114). Understanding the underlying molecular mechanisms of DCLK1 is important in identifying small molecules that can effectively bind and inhibit DCLK1. In addition, targeting the interacting partners of DCLK1 may be an effective treatment strategy.

 Acknowledgements

Not applicable.

 Funding

No funding was received.

 Availability of data and materials

Not applicable.

 Authors' contributions

MV drafted the initial manuscript. MB generated ad interpreted the images and contributed to a concept that deals with the interaction of DCLK1 protein. SR critically reviewed the manuscript for important intellectual content. AT conceptualized the hypothesis and performed a critical review of the paper. Data authentication is not applicable. All authors have read and approved the final manuscript.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References The Human Protein ATLAS: DCLK1Human Protein ATLAS Summaryhttps://www.proteinatlas.org/ENSG00000133083-DCLK1June82020 National Center for Biotechnology Information (NCBI)DCLK1 doublecortin like kinase 1 [Homo sapiens (human)]NCBIBethesda, MD2020https://www.ncbi.nlm.nih.gov/gene/9201June82020 VreugdenhilEKolkSMBoekhoornKFitzsimonsCPSchaafMSchoutenTSarabdjitsinghASibugRLucassenPJDoublecortin-like, a microtubule-associated protein expressed in radial glia, is crucial for neuronal precursor division and radial process stabilityEur J Neurosci25635648200710.1111/j.1460-9568.2007.05318.x17313568 WalkerTLYasudaTAdamsDJBartlettPFThe doublecortin-expressing population in the developing and adult brain contains multipotential precursors in addition to neuronal-lineage cellsJ Neurosci2737343742200710.1523/JNEUROSCI.5060-06.200717409237 LinPTGleesonJGCorboJCFlanaganLWalshCADCAMKL1 encodes a protein kinase with homology to doublecortin that regulates microtubule polymerizationJ Neurosci2091529161200010.1523/JNEUROSCI.20-24-09152.200011124993 MatsumotoNPilzDTLedbetterDHGenomic structure, chromosomal mapping, and expression pattern of human DCAMKL1 (KIAA0369), a homologue of DCX (XLIS)Genomics56179183199910.1006/geno.1998.567310051403 BurgessHAReinerOAlternative splice variants of doublecortin-like kinase are differentially expressed and have different kinase activitiesJ Biol Chem2771769617705200210.1074/jbc.M11198120011884394 HirshorenNCohenJNeumanTWeinbergerJMEliasharRDCLK1 expression in gastrointestinal stem cells and neoplasiaJ Cancer Ther Res112201210.7243/2049-7962-1-12 LiuHWenTZhouYFanXDuTGaoTLiLLiuJYangLYaoJDCLK1 plays a metastatic-promoting role in human breast cancer cellsBiomed Res Int20191061979201931223610 SakaguchiMHisamoriSOshimaNSatoFShimonoYSakaiYMIR-137 regulates the tumorigenicity of colon cancer stem cells through the inhibition of DCLK1Mol Cancer Res14354362201610.1158/1541-7786.MCR-15-038026747706 ChandrakesanPYaoJQuDMayRWeygantNGeYAliNSurebanSMGudeMVegaKDclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cellsMol Cancer1630201710.1186/s12943-017-0594-y28148261 ChandrakesanPPanneerselvamJQuDWeygantNMayRBronzeMSHouchenCWRegulatory Roles of Dclk1 in epithelial mesenchymal transition and cancer stem cellsJ Carcinog Mutagen7257201627335684 LiuWWangSSunQYangZLiuMTangHDCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-κB pathway in colorectal cancerInt J Cancer14220682079201810.1002/ijc.3123229277893 SurebanSMMayRRamalingamSSubramaniamDNatarajanGAnantSHouchenCWSelective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanismGastroenterology13764959, 659.e1-2200910.1053/j.gastro.2009.05.00419445940 RoyBCAhmedIRamalingamSJalaVHaribabuBRamamoorthyPAshcraftJValentinoJAnantSSampathVUmarSCo-localization of autophagy-related protein p62 with cancer stem cell marker dclk1 may hamper dclk1′s elimination during colon cancer development and progressionOncotarget1023402354201910.18632/oncotarget.2668431040926 GerbeFLegraverendCJayPThe intestinal epithelium tuft cells: Specification and functionCell Mol Life Sci6929072917201210.1007/s00018-012-0984-722527717 DelGiornoKENaeemRFFangLChungCYRamosCLuhtalaNO'ConnorCHunterTManorUWahlGMTuft cell formation reflects epithelial plasticity in pancreatic injury: Implications for modeling human pancreatitisFront Physiol1188202010.3389/fphys.2020.0008832116793 TingHAvon MoltkeJThe Immune function of tuft cells at gut mucosal surfaces and beyondJ Immunol20213211329201910.4049/jimmunol.180106930782851 ShuTTsengHCSapirTSternPZhouYSanadaKFischerACoquelleFMReinerOTsaiLHDoublecortin-like kinase controls neurogenesis by regulating mitotic spindles and M phase progressionNeuron492539200610.1016/j.neuron.2005.10.03916387637 LiuJSSchubertCRFuXFourniolFJJaiswalJKHoudusseAStultzCMMooresCAWalshCAMolecular basis for specific regulation of neuronal kinesin-3 motors by doublecortin family proteinsMol Cell47707721201210.1016/j.molcel.2012.06.02522857951 ShinEKashiwagiYKuriuTIwasakiHTanakaTKoizumiHGleesonJGOkabeSDoublecortin-like kinase enhances dendritic remodelling and negatively regulates synapse maturationNat Commun41440201310.1038/ncomms244323385585 QinJMizuguchiMItohMTakashimaSA novel migration-related gene product, doublecortin, in neuronal migration disorder of fetuses and infants with Zellweger syndromeActa Neuropathol100168173200010.1007/s00401990015410963364 LipkaJKapiteinLCJaworskiJHoogenraadCCMicrotubule-binding protein doublecortin-like kinase 1 (DCLK1) guides kinesin-3-mediated cargo transport to dendritesEMBO J35302318201610.15252/embj.20159292926758546 LuYMaruyamaJKuwataKFukudaHIwasaHArimoto-MatsuzakiKSugimuraHHataYDoublecortin-like kinase 1 compromises DNA repair and induces chromosomal instabilityBiochem Biophys Reports16130137201810.1016/j.bbrep.2018.10.01430417131 O'ConnellMRSarkarSLuthraGKOkugawaYToiyamaYGajjarAHQiuSGoelASinghPEpigenetic changes and alternate promoter usage by human colon cancers for expressing DCLK1-isoforms: Clinical ImplicationsSci Rep514983201510.1038/srep1498326447334 SinghPO'ConnellMShubhashishSEpigenetic regulation of human DCLK-1 gene during coloncarcinogenesis: Clinical and mechanistic implicationsStem Cell Investig351201610.21037/sci.2016.09.0727777940 BarkerNCleversHLineage tracing in the intestinal epitheliumCurr Protoc Stem Cell Biol Chapter5Unit5A.4201020443207 KretzschmarKWattFMLineage tracingCell1483345201210.1016/j.cell.2012.01.00222265400 SimonsBDCleversHStem cell self-renewal in intestinal cryptExp Cell Res3127192724201110.1016/j.yexcr.2011.07.01021787769 TanDWBarkerNIntestinal stem cells and their defining nicheCurr Top Dev Biol10777107201410.1016/B978-0-12-416022-4.00003-224439803 WestphalenCBAsfahaSHayakawaYTakemotoYLukinDJNuberAHBrandtnerASetlikWRemottiHMuleyALong-lived intestinal tuft cells serve as colon cancer-initiating cellsJ Clin Invest12412831295201410.1172/JCI7343424487592 MayRQuDWeygantNChandrakesanPAliNLightfootSALiLSurebanSMHouchenCWBrief report: Dclk1 deletion in tuft cells results in impaired epithelial repair after radiation injuryStem Cells32822827201410.1002/stem.156624123696 QuDWeygantNMayRChandrakesanPMadhounMAliNSurebanSMAnGSchlosserMJHouchenCWAblation of doublecortin-like kinase 1 in the colonic epithelium exacerbates dextran sulfate sodium-induced colitisPLoS One10e0134212201510.1371/journal.pone.013421226285154 WestphalenCBTakemotoYTanakaTMacchiniMJiangZRenzBWChenXOrmannsSNagarKTailorYDclk1 defines quiescent pancreatic progenitors that promote injury-induced regeneration and tumorigenesisCell Stem Cell18441455201610.1016/j.stem.2016.03.01627058937 MiddelhoffMWestphalenCBHayakawaYYanKSGershonMDWangTCQuanteMDclk1-expressing tuft cells: Critical modulators of the intestinal niche?Am J Physiol Gastrointest Liver Physiol313G285G299201710.1152/ajpgi.00073.201728684459 ChandrakesanPMayRWeygantNQuDBerryWLSurebanSMAliNRaoCHuyckeMBronzeMSHouchenCWIntestinal tuft cells regulate the ATM mediated DNA Damage response via Dclk1 dependent mechanism for crypt restitution following radiation injurySci Rep637667201610.1038/srep3766727876863 SurebanSMMayRWeygantNQuDChandrakesanPBannerman-MensonEAliNPantazisPWestphalenCBWangTCHouchenCWXMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanismCancer Lett351151161201410.1016/j.canlet.2014.05.01124880079 GagliardiGGoswamiMPasseraRBellowsCFDCLK1 immunoreactivity in colorectal neoplasiaClin Exp Gastroenterol53542201210.2147/CEG.S3028122557932 QuDWeygantNYaoJChandrakesanPBerryWLMayRPittsKHusainSLightfootSLiMOverexpression of DCLK1-AL increases tumor cell invasion, drug resistance, and KRAS activation and can be targeted to inhibit tumorigenesis in pancreatic cancerJ Oncol20196402925201910.1155/2019/640292531467540 PowrózekTKrawczykPNicośMKuźnar-KamińskaBBatura-GabryelHMilanowskiJMethylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patientsClin Transl Oncol18398404201610.1007/s12094-015-1382-z26311076 WhortonJSurebanSMMayRQuDLightfootSAMadhounMJohnsonMTierneyWMMapleJTVegaKJHouchenCWDCLK1 is detectable in plasma of patients with barrett's esophagus and esophageal adenocarcinomaDig Dis Sci60509513201510.1007/s10620-014-3347-425283374 WuXQuDWeygantNPengJHouchenCWCancer stem cell marker DCLK1 correlates with tumorigenic immune infiltrates in the colon and gastric adenocarcinoma microenvironmentsCancers (Basel)12274202010.3390/cancers1202027431979136 ItoHTanakaSAkiyamaYShimadaSAdikrisnaRMatsumuraSAiharaAMitsunoriYBanDOchiaiTDominant expression of DCLK1 in human pancreatic cancer stem cells accelerates tumor invasion and metastasisPLoS One11e0146564201610.1371/journal.pone.014656426764906 GaoTWangMXuLWenTLiuJAnGDCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancerJ Cancer Res Clin Oncol14221312140201610.1007/s00432-016-2218-027520310 SurebanSMMayRQuDWeygantNChandrakesanPAliNLightfootSAPantazisPRaoCVPostierRGHouchenCWDCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancerPLoS One8e73940201310.1371/journal.pone.007394024040120 GeYWeygantNQuDMayRBerryWLYaoJChandrakesanPZhengWZhaoLZhaoKLAlternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancerInt J Cancer14311621175201810.1002/ijc.3140029577277 FanCBYanXHTianMZhangSLiuJLShengYXDongLZhangWLLong non-coding RNA NEAT1 regulates Hodgkin's lymphoma cell proliferation and invasion via miR-448 mediated regulation of DCLK1Eur Rev Med Pharmacol Sci2462196227202032572888 AliNNguyenCBChandrakesanPWolfRFQuDMayRGoretskyTFaziliJBarrettTALiMDoublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical β-catenin-dependent mechanismSci Rep1010578202010.1038/s41598-020-67401-y32601309 GzilAZarębskaIBursiewiczWAntosikPGrzankaDSzylbergŁMarkers of pancreatic cancer stem cells and their clinical and therapeutic implicationsMol Biol Rep4666296645201910.1007/s11033-019-05058-131486978 SubramaniamDAnguloPPonnurangamSDandawatePRamamoorthyPSrinivasanPIwakumaTWeirSJChastainKAnantSSuppressing STAT5 signaling affects osteosarcoma growth and stemnessCell Death Dis11149202010.1038/s41419-020-2335-132094348 FeslerALiuHJuJModified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1Oncotarget923672383201810.18632/oncotarget.2341429416778 KantaraCO'ConnellMSarkarSMoyaSUllrichRSinghPCurcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNACancer Res7424872498201410.1158/0008-5472.CAN-13-353624626093 SarkarSO'ConnellMROkugawaYLeeBSToiyamaYKusunokiMDabovalRDGoelASinghPFOXD3 regulates csc marker, dclk1-s, and invasive potential: Prognostic implications in colon cancerMol Cancer Res1516781691201710.1158/1541-7786.MCR-17-028728851816 WeygantNGeYQuDKaddisJSBerryWLMayRChandrakesanPBannerman-MensonEVegaKJTomasekJJSurvival of patients with gastrointestinal cancers can be predicted by a surrogate microRNA signature for cancer stem-like cells marked by DCLK1 kinaseCancer Res7640904099201610.1158/0008-5472.CAN-16-002927287716 MirzaeiAMadjdZKadijaniAATavakoli-YarakiMModarresiMHVerdiJAkbariATavoosidanaGEvaluation of circulating cellular DCLK1 protein, as the most promising colorectal cancer stem cell marker, using immunoassay based methodsCancer Biomark17301311201610.3233/CBM-16064227802206 BaileyJMAlsinaJRasheedZAMcAllisterFMFuYYPlentzRZhangHPasrichaPJBardeesyNMatsuiWDCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in pre-invasive pancreatic cancerGastroenterology146245256201410.1053/j.gastro.2013.09.05024096005 VedeldHMSkotheimRILotheRALindGEThe recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancerEpigenetics9346350201410.4161/epi.2758224384857 MirzaeiATavoosidanaGModarressiMHRadAAFazeliMSShirkoohiRTavakoli-YarakiMMadjdZUpregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patientsTumor Biol3648014810201510.1007/s13277-015-3132-925631749 SarkarSPopovVLO'ConnellMRStevensonHLLeeBSObeidRALuthraGKSinghPA novel antibody against cancer stem cell biomarker, DCLK1-S, is potentially useful for assessing colon cancer risk after screening colonoscopyLab Invest9712451261201710.1038/labinvest.2017.4028414327 KrishnamacharyBSubramaniamDDandawatePPonnurangamSSrinivasanPRamamoorthyPUmarSThomasSMDharASepterSTargeting transcription factor TCF4 by γ-Mangostin, a natural xanthoneOncotarget1055765591201910.18632/oncotarget.2715931608135 ZhouBSunCHuXZhanHZouHFengYQiuFZhangSWuLZhangBMicroRNA-195 suppresses the progression of pancreatic cancer by targeting DCLK1Cell Physiol Biochem4418671881201710.1159/00048587629224010 DengHQianqianGTingJAiminYmiR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1Biomed Pharmacother10610721081201810.1016/j.biopha.2018.07.02430119173 JiDZhanTLiMYaoYJiaJYiHQiaoMXiaJZhangZDingHEnhancement of sensitivity to chemo/radiation therapy by using miR-15b against DCLK1 in colorectal cancerStem Cell Reports1115061522201810.1016/j.stemcr.2018.10.01530449704 LiJWangYGeJLiWYinLZhaoZLiuSQinHYangJWangLDoublecortin-like kinase 1 (DCLK1) regulates B cell-specific moloney murine leukemia virus insertion site 1 (Bmi-1) and is associated with metastasis and prognosis in pancreatic cancerCell Physiol Biochem51262277201810.1159/00049522830453285 RangarajanPSubramaniamDPaulSKwatraDPalaniyandiKIslamSHariharSRamalingamSGutheilWPuttySCrocetinic acid inhibits hedgehog signaling to inhibit pancreatic cancer stem cellsOncotarget62766127673201510.18632/oncotarget.487126317547 National Institutes of Health (NIH)DCX gene doublecortin-Genetics Home ReferenceNIHBethesda, MD2020https://ghr.nlm.nih.gov/gene/DCXAugust252020 National Center for Biotechnology Information (NCBI)DCX doublecortin [Homo sapiens (human)]NCBIBethesda, MD2020https://www.ncbi.nlm.nih.gov/gene/1641August252020 HoreshDSapirTFrancisFWolfSGCaspiMElbaumMChellyJReinerODoublecortin, a stabilizer of microtubulesHum Mol Genet815991610199910.1093/hmg/8.9.159910441322 GleesonJGPeterTLFlanaganLAWalshCADoublecortin is a microtubule-associated protein and is expressed widely by migrating neuronsNeuron23257271199910.1016/S0896-6273(00)80778-310399933 FrancisFKoulakoffABoucherDChafeyPSchaarBVinetMCFriocourtGMcDonnellNReinerOKahnADoublecortin is a developmentally regulated, microtubule- associated protein expressed in migrating and differentiating neuronsNeuron23247256199910.1016/S0896-6273(00)80777-110399932 STRING: DCLK1 protein (human)-STRING coexpression viewhttps://string-db.org/cgi/network?taskId=bnI9rrwHb9Jm&sessionId=bLIMVpiJ6j48June292020 KoizumiHTanakaTGleesonJGDoublecortin-like kinase functions with doublecortin to mediate fiber tract decussation and neuronal migrationNeuron495566200610.1016/j.neuron.2005.10.04016387639 HuttlinELTingLBrucknerRJGebreabFGygiMPSzpytJTamSZarragaGColbyGBaltierKThe BioPlex Network: A systematic exploration of the human interactomeCell162425440201510.1016/j.cell.2015.06.04326186194 HuttlinELBrucknerRJPauloJACannonJRTingLBaltierKColbyGGebreabFGygiMPParzenHArchitecture of the human interactome defines protein communities and disease networksNature545505509201710.1038/nature2236628514442 SlepakTISalayLDLemmonVPBixbyJLDyrk kinases regulate phosphorylation of doublecortin, cytoskeletal organization, and neuronal morphologyCytoskeleton (Hoboken)69514527201210.1002/cm.2102122359282 National Center for Biotechnology Information (NCBI)ANK2 ankyrin 2 [Homo sapiens (human)]NCBIBethesda, MD2020https://www.ncbi.nlm.nih.gov/gene?cmd=Retrieve&dopt=full_report&list_uids=287June292020 LiuZQHeWFWuYJZhaoSLWangLOuyangYYTangSYLncRNA SNHG1 promotes EMT process in gastric cancer cells through regulation of the miR-15b/DCLK1/Notch1 axisBMC Gastroenterol20156202010.1186/s12876-020-01272-532423385 MengQBYuJCKangWMMaZQZhouWXLiJZhouLCaoZJTianSBExpression of doublecortin-like kinase 1 in human gastric cancer and its correlation with prognosisZhongguo Yi Xue Ke Xue Yuan Xue Bao356396442013(In Chinese)24382242 CaoWWeiWZhanZXieDXieYXiaoQRegulation of drug resistance and metastasis of gastric cancer cells via the microRNA647-ANK2 axisInt J Mol Med4119581966201829328428 CaoWWeiWZhanZXieDXieYXiaoQRole of miR-647 in human gastric cancer suppressionOncol Rep3714011411201710.3892/or.2017.538328098914 GirottoGVuckovicDBunielloALorente-CánovasBLewisMGaspariniPSteelKPExpression and replication studies to identify new candidate genes involved in normal hearing functionPLoS One9e85352201410.1371/journal.pone.008535224454846 WellsHRRNewmanTAWilliamsFMKGenetics of age-related hearing lossJ Neurosci Res9816981704202010.1002/jnr.2454931989664 VuckovicDIdentification of the genetic determinants of hearing loss by means of genetic isolatesUniversità degli studi di TriesteTrieste2015https://www.openstarts.units.it/handle/10077/10847March22015 Cancer Genetics Web: MSI1Gene Summaryhttp://www.cancerindex.org/geneweb/MSI1.htmAugust292020 SongXZhouCZhouSZhangLFengGZhaoDHuangFThe expression patterns of Mis1 is related with the glioma grade and the cytoplasmic Mis1 promotes angiogenesisTissue Cell4516201310.1016/j.tice.2012.08.00623017339 GaoCHanCYuQZhouJGuanYLiNZhouJTianYZhangYDownregulation of Msi1 suppresses the growth of human colon cancer by targeting p21cip1Int J Oncol46732740201510.3892/ijo.2014.274925394506 MoghbeliMForghanifardMMSadrizadehAMozaffariHMGolmakaniEAbbaszadeganMRRole of Msi1 and MAML1 in regulation of notch signaling pathway in patients with esophageal squamous cell carcinomaJ Gastrointest Cancer46365369201510.1007/s12029-015-9753-926294058 SurebanSMQuDHouchenCWRegulation of miRNAs by agents targeting the tumor stem cell markers DCLK1, MSI1, LGR5, and BMI1Curr Pharmacol Rep1217222201510.1007/s40495-014-0006-626366338 SakakibaraSNakamuraYYoshidaTShibataSKoikeMTakanoHUedaSUchiyamaYNodaTOkanoHRNA-binding protein Musashi family: Roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablationProc Natl Acad Sci USA991519415199200210.1073/pnas.23208749912407178 KimHLeeCKimWHMaengYHJangBGExpression profile of intestinal stem cell markers in colitis-associated carcinogenesisSci Rep76533201710.1038/s41598-017-06900-x28747693 YeFZhouCChengQShenJChenHStem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cellsBMC Cancer8108200810.1186/1471-2407-8-10818419830 SurebanSMMayRQuDAsfaSAnantSHouchenCWKnockdown of Musashi-1 Results in Tumor Growth Arrest Through Inhibition of c-MYC, Notch-1 and EMT by Let-7a, Mir-144 and Mir-200a MicroRNAs dependent mechanisms respectivelyGastroenterology140S48201110.1016/S0016-5085(11)60194-7 VoDTQiaoMSmithADBurnsSCBrennerAJPenalvaLOFThe oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAsRNA Biol8817828201110.4161/rna.8.5.1604121881409 KimCKYangVWBialkowskaABThe role of intestinal stem cells in epithelial regeneration following radiation-induced gut injuryCurrent Stem Cell Rep3320332201710.1007/s40778-017-0103-729497599 GeneMANIADCLK1: H. sapienshttps://genemania.org/September172020 GeneCardsTNIK Gene (Protein Coding)https://www.genecards.org/cgi-bin/carddisp.pl?gene=TNIKSeptember172020 GeneCardsCALM1 Gene (Protein Coding)https://www.genecards.org/cgi-bin/carddisp.pl?gene=CALM1September172020 GeneCardsCDCA8 Gene (Protein Coding)https://www.genecards.org/cgi-bin/carddisp.pl?gene=CDCA8&keywords=CDCA8September172020 GeneCardsDGUOK Gene (Protein Coding)https://www.genecards.org/cgi-bin/carddisp.pl?gene=DGUOK&keywords=DGUOKSeptember172020 GeneCardsFBLIM1 Gene (Protein Coding)https://www.genecards.org/cgi-bin/carddisp.pl?gene=FBLIM1&keywords=FBLIM1September172020 GeneCardsHAX1 Gene (Protein Coding)https://www.genecards.org/cgi-bin/carddisp.pl?gene=HAX1&keywords=Dclk1September172020 GeneCardsNUFIP1 Gene (Protein Coding)https://www.genecards.org/cgi-bin/carddisp.pl?gene=NUFIP1&keywords=NUFIp1September172020 WeygantNQuDBerryWLMayRChandrakesanPOwenDBSurebanSMAliNJanknechtRHouchenCWSmall molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1Mol Cancer13103201410.1186/1476-4598-13-10324885928 YanRLiJZhouYYaoLSunRXuYGeYAnGInhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancerLife Sci241117150202010.1016/j.lfs.2019.11715031837335 LorenzoNSabinaDMGuidoCIlaria GraziaZSamiraSValeriaADanieleCDilettaOAntonellaGMarcoMDCLK1, a putative stem cell marker in human cholangiocarcinomaHepatology73144159202110.1002/hep.3157132978808 KumarCP T VLArunachalamAStructure based pharmacophore study to identify possible natural selective PARP-1 trapper as anti-cancer agentComput Biol Chem80314323201910.1016/j.compbiolchem.2019.04.01831078910 FuYYeTLiuYXWangJYeFBased on the virtual screening of multiple pharmacophores, docking and molecular dynamics simulation approaches toward the discovery of novel HPPD inhibitorsInt J Mol Sci215546202010.3390/ijms2115554632756361 ShiriFPirhadiSGhasemiJBDynamic structure based pharmacophore modeling of the Acetylcholinesterase reveals several potential inhibitorsJ Biomol Struct Dyn3718001812201910.1080/07391102.2018.146828129695192 BenafqirMHsiniALaabdMLaktifTAit AddiAAlbourineAAlemNEApplication of Density Functional Theory computation (DFT) and Process Capability Study for performance evaluation of Orthophosphate removal process using Polyaniline@Hematite-titaniferous sand composite (PANI@HTS) as a substrateSep Purif Technol236116286202010.1016/j.seppur.2019.11628632322159 ZhaoZLiEQinYLiuXZouYWuHZhuTDensity functional theory (DFT) studies of vanadium-titanium based selective catalytic reduction (SCR) catalystsJ Environ Sci (China)90119137202010.1016/j.jes.2019.11.00832081309 Vafaei-NezhadMGhiasiRShafieiFConformational Analysis of 2-halo-1,3,2-dioxaphosphinanes: A density functional theory (DFT) InvestigationChem Methodol4161171202010.33945/SAMI/CHEMM.2020.2.6 SchallerDŠribarDNoonanTDengLNguyenTNPachSMachalzBermudezMWolberGNext generation 3D pharmacophore modelingWIREs Comput Mol Sci10e1468202010.1002/wcms.1468 LeeJYKriegerJMLiHBaharIPharmmaker: Pharmacophore modeling and hit identification based on druggability simulationsProtein Sci297686202010.1002/pro.373231576621 PalSKumarVKunduBBhattacharyaDPreethyNReddyMPTalukdarALigand-based pharmacophore modeling, virtual screening and molecular docking studies for discovery of potential topoisomerase i inhibitorsComput Struct Biotechnol J17291310201910.1016/j.csbj.2019.02.00630867893

A timeline illustrating current breakthroughs and findings surrounding DCLK1 in colorectal cancer. DCLK1, doublecortin-like kinase protein 1; LRRk2-IN-1, leucine-rich repeat kinase 2 inhibitor 1.

Networks generated using Cytoscape software (v.3.8.2; on Java 11.0.6 by AdoptOpenJDK) to elucidate the interaction between DCLK1 and different proteins. (A) Co-expression patterns, (B) consolidated pathways and (C) physical interactions. Circles represent proteins; DCLK1, doublecortin-like kinase protein 1.

Doublecortin-like kinase protein 1 protein bound to the kinase domain of small molecule LRRk2-IN-1 (left). Chemical structure of LRRk2-IN-1 (right). LRRk2-IN-1, leucine-rich repeat kinase 2 inhibitor 1.

Comparing three of the most prevalent types of cancer and the functions of DCLK1.

Characteristic Colorectal cancer Pancreatic cancer Gastric cancer
Role of DCLK1 Promotes EMT Promotes stem cell pluripotency, angiogenesis and EMT Cancer initiation, progression and EMT
Proteins regulated by DCLK1 P65 subunit of the NF-kB Pluripotency factors, such as P65 subunit of the NF-κB
transcription factor; Sp1 transcription factor OCT4, SOX2, c-MYC, LIN28, NANOG and KLF4 transcription factor; Sp1 transcription factor
Pathways regulated by DCLK1 PI3K/Akt pathway NOTCH signalling pathway NOTCH, NF-κB, KRAS, and WNT molecular signalling pathways
Therapeutic treatment Targeting DCLK1 with inhibitors, such as LRRk2-IN-1 small molecule Downregulation of DCLK1 upregulates tumor suppressor mRNAs Targeting DCLK1 with inhibitors, such as LRRk2-IN-1 small molecule

DCLK1, doublecortin-like kinase protein 1; EMT, epithelial-to-mesenchymal transition; NF-κB, nuclear factor κ light chain enhancer of activated B cells; OCT4, octamer-binding transcription factor 4; SOX2, SRY (sex determining region Y)-box 2; KLF4, Kruppel-like factor 4; LRRk2-In-1, Leucine-rich repeat kinase 2 Inhibitor 1.